Pharma channel feed

Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

6 years ago
Deals
R&D

ICER up­date on Duchenne drugs push­es up price es­ti­mates for Ex­ondys 51, Em­flaza ahead of Ju­ly pan­el re­view

6 years ago

Analy­sis: In most of the Big Phar­ma world, R&D spend­ing tow­ers over rev­enue from new drugs. Guess who beat the odds

6 years ago
R&D
Biotech Voices

New peanut al­ler­gy ther­a­pies aren’t as ef­fec­tive — or near­ly as in­ex­pen­sive — as ab­sti­nence, says ICER

6 years ago

White House changes course to kill re­bate re­form

6 years ago

Sup­ply con­straints push EpiPen ri­val mak­er Am­neal to re­struc­ture, shares fall

6 years ago

Fed­er­al judge scut­tles Trump's rule man­dat­ing drug prices in TV ads

6 years ago
FDA+

Ex­ec­u­tive or­der un­der con­struc­tion to peg US drug prices to low­est prices abroad, Trump says

6 years ago

Alex­ion's cash cow Soliris just got fat­ter as FDA green­lights an­oth­er block­buster in­di­ca­tion

6 years ago

Sanofi/Re­gen­eron mus­cle ahead of a ri­val No­var­tis/Roche team, win first ap­proval in key rhi­nos­i­nusi­tis field

6 years ago

Bris­tol-My­ers star Op­di­vo fails sur­vival test in a matchup with Nex­avar aimed at shak­ing up the big HCC mar­ket

6 years ago
R&D

FDA spurns hay fever drug from In­di­a's Glen­mark

6 years ago
FDA+

Why would the FDA ap­prove an­oth­er con­tro­ver­sial drug to spur a woman’s li­bido with these da­ta? And why no ex­pert pan­el re­view?

6 years ago
Bioregnum
Opinion

J&J's Es­ke­t­a­mine, at cur­rent price, is 'low val­ue for mon­ey' — ICER

6 years ago

Which top 10 big phar­mas have the most to gain — or lose — over the next 5 years?

6 years ago

'Our lega­cy mat­ter­s': Mer­ck maps out Keytru­da king­dom while spot­light­ing ad­vances in vac­cines, hos­pi­tal care

6 years ago
R&D

In starved an­tibi­ot­ic field, Melin­ta soars as FDA grants speedy drug re­view

6 years ago
R&D

An­a­lyst call with Al­ler­gan ex­ecs stokes an­tic­i­pa­tion of a plan to split the com­pa­ny in ‘a month or two’

6 years ago
Deals

Chica­go biotech ar­gues blue­bird, Third Rock 'killed' its ri­val, pi­o­neer­ing tha­lassemia gene ther­a­py in law­suit

6 years ago
People

A new num­ber 1 drug? Keytru­da tapped to top the 10 biggest block­busters on the world stage by 2024

6 years ago

Iron­wood, Al­ler­gan add a slate of PhI­I­Ib da­ta to its Linzess pitch for physi­cians, pa­tients

6 years ago

Step­ping on Roche's toes, Mer­ck cuts in­to SCLC niche with third-line Keytru­da OK

6 years ago

As­traZeneca/Mer­ck win EU ap­proval for front­line main­te­nance treat­ment of ovar­i­an can­cer, months af­ter FDA en­dorse­ment

6 years ago

Drug­mak­ers sue HHS for try­ing to add prices to DTC ads

6 years ago
FDA+
First page Previous page 266267268269270271272 Next page Last page
A service from the Financial Times